NEI Podcast

In this episode, Dr. Andy Cutler speaks with Dr. Jonathan Meyer to dispel common myths about antipsychotic treatment, from concerns about sedation, personality change, and brain effects to misunderstandings about safety, long-acting injectables, and clozapine. The discussion focuses on what the evidence actually shows about efficacy, risk, and recovery, and how clinicians can communicate more clearly and confidently with patients and families. 

Jonathan Meyer, MD, DLFAPA, is a Voluntary Clinical Professor of Psychiatry at the University of California, San Diego. He serves as a Senior Academic Advisor to the California Department of State Hospitals, is a psychopharmacology consultant to the first episode psychosis program at Balboa Naval Medical Center, and has published extensively on psychopharmacology, including co-authoring The Clozapine Handbook, The Clinical Use of Antipsychotic Plasma Levels, and The Lithium Handbook with Dr. Stephen Stahl. 

Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. 

Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26 

Register today at nei.global/spring 
Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

YouTube: https://nei.global/youtube 


Instagram: https://nei.global/instagram 


LinkedIn: https://nei.global/linkedin 


Facebook: https://nei.global/facebook 


X: https://nei.global/twitter

In this episode, Dr. Andy Cutler and Dr. Jeff Strawn unpack common misconceptions that complicate real-world use of antidepressants. They review evidence on efficacy, suicidality risk, mechanisms, and early side effects, and discuss how to navigate hesitancy and misinformation. The conversation also addresses when to start medication, how to balance caution with timely intervention in youth, and practical ways to strengthen trust and therapeutic alliance. 

Jeffrey R. Strawn, MD, FAACAP, is a Professor of Psychiatry, Pediatrics, and Clinical & Translational Pharmacology at the University of Cincinnati (UC) in Cincinnati, Ohio. He is the Director of the UC Anxiety Disorders Research Program and the Associate Vice Chair of Research in the Department of Psychiatry & Behavioral Neuroscience at UC.  

Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. 

Resources 

Zhang K et al. Functional connectivity predicting transdiagnostic treatment outcomes in internalizing psychopathologies. JAMA Netw Open 2025;8(9):e2530008. doi: 10.1001/jamanetworkopen.2025.30008 

Lagerberg T et al. Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study. Neuropsychopharmacology 2022;47(4):817-23. doi: 10.1038/s41386-021-01179-z 
Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 
Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

YouTube: https://nei.global/youtube 


Instagram: https://nei.global/instagram 


LinkedIn: https://nei.global/linkedin 


Facebook: https://nei.global/facebook 


X: https://nei.global/twitter

As 2025 comes to an end, we revisit our most downloaded episode of the year. Join Dr. Andy Cutler and Dr. Carla Sharp as they explore the current conceptualization of borderline personality disorder (BPD), including diagnostic challenges, evidence-based treatments, and strategies to reduce stigma by framing BPD as a treatable condition. The conversation also highlights recent updates to the APA's BPD guidelines and what they mean for clinical practice. 

Carla Sharp, PhD is a distinguished clinical psychologist specializing in developmental psychopathology, particularly borderline personality disorder (BPD). She is a professor in the Clinical Psychology Doctoral Program and serves as the Associate Dean for Faculty and Research at the University of Houston. Additionally, she directs both the Adolescent Diagnosis, Assessment, Prevention, and Treatment Center and the Developmental Psychopathology Lab at the university.   

Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. 

Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

YouTube: https://nei.global/youtube


Instagram: https://nei.global/instagram


LinkedIn: https://nei.global/linkedin


Facebook: https://nei.global/facebook


X: https://nei.global/twitter

Join Drs. Andy Cutler and Roger McIntyre as they discuss the most significant advancements in psychopharmacology over the past year. Their conversation highlights groundbreaking developments and innovations in the field of psychiatry.  

Roger McIntyre, MD, FRCPC, is a globally recognized psychiatrist and psychopharmacologist who holds pivotal roles in academia, research, and leadership. His research primarily focuses on the phenomenology, neurobiology, and development of novel therapeutics for mood disorders. Dr. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.  

Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. 
Resources 

Thanarajah ES et al. Soft drink consumption and depression mediated by gut microbiome alterations. JAMA Psychiatry 2025;82(11):1095–1102. doi:10.1001/jamapsychiatry.2025.2579 

Durgam S et al. Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. J Clin Psychiatry 2025;86(4):25m15848. doi: 10.4088/JCP.25m15848 

Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2025;82(4):395–405. doi: 10.1001/jamapsychiatry.2024.4789 

Aron L et al. Lithium deficiency and the onset of Alzheimer's disease. Nature 2025;645:712–21. doi: 10.1038/s41586-025-09335-x 
Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

YouTube: https://nei.global/youtube 


Instagram: https://nei.global/instagram 


LinkedIn: https://nei.global/linkedin 


Facebook: https://nei.global/facebook 


X: https://nei.global/twitter

In this CME episode, Dr. Andy Cutler talks with Drs. Stephen Stahl and Roger McIntyre about recognizing and managing complex depression, particularly major depressive episodes with mixed or anxious features. They discuss how these specifiers affect diagnosis, symptom severity, and treatment response, and explore evidence-based strategies for optimizing outcomes through individualized and adjunctive approaches.
Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e270-cme
Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 
Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

YouTube: https://nei.global/youtube 


Instagram: https://nei.global/instagram 


LinkedIn: https://nei.global/linkedin 


Facebook: https://nei.global/facebook 


X: https://nei.global/twitter